Nebojsa Janjic

SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO.

Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO

NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO.